Use of the PATH Alliance® Database to Measure Adherence to IDSA Guidelines for the Therapy of Candidemia

D. HORN, MD1, D. NEOFYTOS, MD1, J. FISHMAN, MD2, W. STEINBACH, MD3, E. ANAISSIE, MD4, K. MARR, MD5, M. PFALLER, MD6, A. OLYAEI, PharmD7

Author address: 

1Thomas Jefferson Univ., Phil, PA, 2MA Gen. Hosp., Boston, MA, 3Duke Univ. Med. Ctr., Durham, NC, 4Univ. of AR for Med. Sci., Little Rock, AR, 5Univ. of WA, Seattle, WA, 6Univ. of IA Health Care, Iowa City, IA, 7OR Health Sci. Univ., Portland, OR.

Abstract: 

Background: The PATH Alliance® (Prospective Antifungal Therapy Alliance) is a comprehensive registry collecting data and monitoring trends in epidemiology, diagnosis, treatment and outcomes of patients (pts.) with invasive fungal infections. Methods: Using pt. data from 7/1/04 to 3/31/06, adherence to IDSA guidelines for therapy of candidemia was measured in regards to choice, dosage, length and time to initiation of therapy. Results: 418 adults (11 sites, 56.4±0.8 yrs; 51.7% male) with candidemia and 445 isolates were identified: C. albicans (42.2%), C. glabrata (29.9%), C. parapsilosis (16.6%), C. tropicalis (7.4%), C. krusei (2.5%) and C. lusitaniae (1.1%). Fluconazole was most commonly used (309 courses), followed by caspofungin (197), voriconazole (35), liposomal amphotericin B (34), unknown due to blinded clinical trial (11), amphotericin B deoxycholate (9), amphotericin B lipid complex (6). Sequential therapy was common; combination therapy was rare (
2006

abstract No: 

558

Full conference title: 

Infectious Diseases Society of America, 44th Annual Meeting
    • IDSA 44th